About Boston Biomedical
It is a fully integrated oncology drug research and development company with expertise in drug discovery, crystallography, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, CMC (chemistry, manufacturing, and control), global clinical trials, and regulatory affairs. In a short time, our scientists have established a track record of accomplishments, including advancing the research and development of multiple compounds and programs.
The company was founded in November 2006 by Chiang J. Li, M.D., and was acquired in 2012 by Sumitomo Dainippon Pharma Co., Ltd. In January 2017, Sumitomo Dainippon Pharma also acquired Tolero Pharmaceuticals, a U.S.-based biotechnology company specializing in research and development of therapeutic agents in the areas of oncology and hematological disorders. This acquisition expanded Sumitomo Dainippon Pharma’s oncology and hematology portfolios.
In April 2017, industry veteran and former Chief Operating Officer Patricia S. Andrews was appointed to the role of Chief Executive Officer. Since joining the company in 2013, Ms. Andrews has been a key driving force leading all aspects of commercial operations and medical affairs. Ms. Andrews’ extensive experience and proven track record of operational success will be instrumental in driving the company forward into the next stage of growth and innovation through expanding its robust clinical pipeline, initiating additional clinical studies for its first-in-class compounds across multiple tumor types, and setting the foundation for future commercialization of late-stage compounds.
Cancer stem cells (CSCs) possess the defining characteristic of stemness—the ability to self-renew and differentiate. Unlike normal stem cells, which differentiate into healthy, mature cell types, CSCs differentiate into cancer cells. Cancer stemness may enable CSCs to metastasize and regrow tumors. Because CSCs are highly resistant to conventional therapies and should be targeted concurrently with non-stem cancer cells, we believe focusing on cancer stemness pathways may lead to advancements in cancer therapy aiming to reduce recurrence and metastases.
Our most advanced research compound, napabucasin (BBI-608), was designed to inhibit cancer stemness pathways by targeting STAT3, and is currently in phase 3 clinical studies. The STAT3 pathway has been identified as critically important for maintaining or promoting a cell’s stemness. We are investigating other research approaches, including: amcasertib (BBI-503), which also targets cancer stemness pathways; a peptide vaccine, DSP-7888, and immune response modifiers. These agents are currently in preclinical and early clinical development. All of these compounds are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or other regulatory agencies.
Our Path Ahead
With a robust pipeline across various stages of clinical development and multiple phase 3 trials underway for napabucasin, we continue to build our commercial capabilities. A core group of seasoned professionals is in place, and we will continue to expand and grow as our research programs mature.
At Boston Biomedical, we have created a unique corporate environment. We leverage our innovation-driven culture, scientific leadership, and drug development expertise to advance the development of novel therapeutics for patients with cancer. Click here to learn more about career opportunities.
The company is located in Cambridge, Massachusetts, at the center of the growing biotechnology industry in the Northeast. As environmental responsibility contributes to public health, our building at 640 Memorial Drive is LEED certified and conducive to our collaborative, forward-thinking approach.
 Reya T, Morrison S, Clarke M, Weissman I. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111.
 Botchkina G, Ojima I. Prostate and colon cancer stem cells as a target for anti-cancer drug development. In: Shostak S, ed. Cancer Stem Cells Theories and Practice. Rijeka, Croatia: InTech; 2011.